Teza Capital Management LLC Purchases New Shares in Hologic, Inc. $HOLX

Key Points

• Teza Capital Management LLC has acquired 4,066 shares of Hologic, Inc. valued at approximately $251,000, as reported in their recent 13F filing.
• Multiple institutional investors, including Beverly Hills Private Wealth and Allworth Financial, have increased their stakes in Hologic, with hedge funds now owning 94.73% of the company's stock.
• Analysts have raised their price targets for Hologic, with Morgan Stanley setting a target of $69.00 and Argus upgrading their rating to buy with a target of $80.00.

Teza Capital Management LLC acquired a new stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 4,066 shares of the medical equipment provider's stock, valued at approximately $251,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Beverly Hills Private Wealth LLC raised its holdings in shares of Hologic by 3.6% in the first quarter. Beverly Hills Private Wealth LLC now owns 5,173 shares of the medical equipment provider's stock valued at $320,000 after purchasing an additional 180 shares during the last quarter. Allworth Financial LP raised its holdings in shares of Hologic by 46.0% in the first quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider's stock valued at $40,000 after purchasing an additional 216 shares during the last quarter. Integrated Advisors Network LLC raised its holdings in shares of Hologic by 5.4% in the first quarter. Integrated Advisors Network LLC now owns 5,603 shares of the medical equipment provider's stock valued at $346,000 after purchasing an additional 289 shares during the last quarter. Townsquare Capital LLC raised its holdings in shares of Hologic by 4.5% in the first quarter. Townsquare Capital LLC now owns 6,763 shares of the medical equipment provider's stock valued at $418,000 after purchasing an additional 293 shares during the last quarter. Finally, Empirical Finance LLC raised its holdings in shares of Hologic by 4.0% in the first quarter. Empirical Finance LLC now owns 8,703 shares of the medical equipment provider's stock valued at $538,000 after purchasing an additional 334 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Hologic Stock Performance

Shares of NASDAQ HOLX traded down $1.93 during mid-day trading on Friday, reaching $64.45. 1,005,460 shares of the company were exchanged, compared to its average volume of 1,330,759. The company's 50-day simple moving average is $66.43 and its 200-day simple moving average is $62.64. The company has a quick ratio of 2.81, a current ratio of 3.55 and a debt-to-equity ratio of 0.52. The stock has a market capitalization of $14.33 billion, a P/E ratio of 26.74, a P/E/G ratio of 2.34 and a beta of 0.57. Hologic, Inc. has a twelve month low of $51.90 and a twelve month high of $84.39.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.05 by $0.03. The company had revenue of $1.02 billion during the quarter, compared to analysts' expectations of $1.01 billion. Hologic had a net margin of 13.79% and a return on equity of 19.69%. Hologic's quarterly revenue was up 1.2% compared to the same quarter last year. During the same quarter last year, the company posted $1.06 EPS. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. As a group, research analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on HOLX. Royal Bank Of Canada upgraded shares of Hologic from a "sector perform" rating to an "outperform" rating and lifted their price objective for the company from $72.00 to $87.00 in a report on Wednesday, August 6th. Needham & Company LLC restated a "hold" rating on shares of Hologic in a report on Tuesday, May 27th. Morgan Stanley boosted their target price on shares of Hologic from $65.00 to $69.00 and gave the stock an "equal weight" rating in a report on Thursday, July 31st. UBS Group boosted their target price on shares of Hologic from $65.00 to $70.00 and gave the stock a "neutral" rating in a report on Thursday, July 31st. Finally, Wall Street Zen upgraded shares of Hologic from a "hold" rating to a "buy" rating in a report on Sunday, September 7th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and eight have assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $78.00.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.